A prospective evaluation of combined modality therapy for breast cancer with ipsilateral supraclavicular node metastases

17025 Background: Based on retrospective data, the most recent breast cancer staging classification changed the status of ipsilateral supaclavicular node mestastases from M1 to N3c. This carried along with it modifications in the treatment of a small subset of breast cancer patients. The aim of this study is to prospectively evaluate surgery and radiation therapy besides systemic treatment in pts with stage IIIC breast cancer. Methods: Phase II single-institution trial. Eligibility: patients with non-metastatic breast cancer and pathological confirmation of ipsilateral supraclaviclular node metastases. Treatment: FAC (fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2) q 21 days × 6; followed by modified radical mastectomy (MRM); adjuvant radiotherapy and tamoxifen (if estrogen and/or progesterone receptors positive - ER/PR). Results: Since May 2002, 22 patients entered the trial, with a median follow-up of 25 months (4–50). Median age was 50 years (29–69). Median tumor size was 6 cm (2.5–15), most patients had T4 disease (77%) and ER/PR positive tumors (64%). All patients underwent MRM after neoadjuvant FAC. Clinical response: 1 (5%) complete, 20 (90%) partial, 1 (5%) minor response. Until December 2006, 13 patients progressed and 7 died. Five patients (23%) had loco-regional relapse and 5 (23%) developed brain metastases. Median estimated progression-free survival was 41 months (14.1–67.8) with median survival not reached. The estimated 2-year progression-free and overall survival rates were 32% and 67%, respectively. Conclusions: Our results, collected in a prospective fashion, are in agreement with previous retrospective studies. Combined-modality treatment for breast cancer with ipsilateral supraclavicular node metastases is recommended. No significant financial relationships to disclose.

Download Full-text

MMTV Prevalence in Breast Cancer Samples in Romania - Do Major Geographical Differences Exist in The World Population?

10.21203/rs.3.rs-682741/v1 ◽

2021 ◽

Author(s):

Zsolt Fekete ◽

Bristena Octavia Terțan ◽

Lajos Ráduly ◽

Dan Tudor Eniu ◽

Rares Buiga ◽

...

Keyword(s):

Breast Cancer ◽

Dna Sequences ◽

Mus Musculus ◽

Breast Tissue ◽

Neoadjuvant Treatment ◽

Metastatic Breast ◽

Radical Mastectomy ◽

Cancer Tissue ◽

World Population ◽

Breast Cancer Patients

Abstract Background Breast cancer, although the most frequently diagnosed malignant tumor in humans, has a less clear etiology compared to other frequent cancer types. Mouse-mammary tumor virus (MMTV) is involved in breast cancer in mice and dogs and might play a role in the etiology of some breast cancers in humans, since it has been identified in 20-40% of breast cancer samples in Western Europe, USA, Australia and some other parts of the world’s population. The purpose of our study was to identify MMTV DNA sequences in breast tissue samples from breast cancer patients who underwent curative surgery in our regional center in Romania, EU. MethodsWe selected 75 patients with non-metastatic breast cancer treated surgically with curative intent, which did not undergo any neoadjuvant treatment. Out of these patients, 50 underwent radical lumpectomy and 25 modified radical mastectomy. We searched using PCR the MMTV-like DNA env sequence in the breast cancer tissue and normal breast tissue obtained from the same patients. ResultsNone of the examined samples was positive for MMTV-like target sequences on PCR.ConclusionsWe could not prove that MMTV plays a role in the etiology of breast cancer in our patient group. This finding is similar to publications of other geographically related research groups and might be due to the fact that only the Mus musculus domesticus mouse species was proven to carry infectious MMTV, but not the Mus musculus musculus species, which is specific to South-Eastern Europe (including Romania) and some parts of Asia.

Download Full-text

Combined Modality Treatment of Local Regionally Advanced Breast Cancer Patients

American Journal of Clinical Oncology ◽

10.1097/00000421-198906000-00006 ◽

1989 ◽

Vol 12 (3) ◽

pp. 208-212 ◽

Cited By ~ 5

Author(s):

Charles L. Loprinzi ◽

Paul W. Rasmussen ◽

Douglass C. Tormey ◽

Paul P. Carbone

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Cancer Patients ◽

Advanced Breast ◽

Combined Modality Treatment ◽

Breast Cancer Patients ◽

Combined Modality

Download Full-text

High Levels of Expression of Cartilage Oligomeric Matrix Protein in Lymph Node Metastases in Breast Cancer Are Associated with Reduced Survival

Cancers ◽

10.3390/cancers13235876 ◽

2021 ◽

Vol 13 (23) ◽

pp. 5876

Author(s):

Konstantinos S. Papadakos ◽

Catharina Hagerling ◽

Lisa Rydén ◽

Anna-Maria Larsson ◽

Anna M. Blom

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Lymph Node ◽

Cancer Patients ◽

Lymph Node Metastases ◽

Matrix Protein ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Primary Tumors ◽

Node Metastases

Cartilage oligomeric matrix protein (COMP) is a regulator of the extracellular matrix and is expressed primarily in the cartilage. Recently, COMP expression was also documented in breast cancer patients both in sera and tumor biopsies, in both of which it could serve as an independent prognostic marker. This study aimed to assess COMP as a potential biomarker in the group of metastatic breast cancer patients. Levels of COMP were measured by ELISA in serum samples of 141 metastatic breast cancer patients. Biopsies from primary tumors, synchronous lymph node metastases, and distant metastases were stained for COMP expression. The levels of serum COMP were higher in patients with ER- and HER2-positive tumors when compared to triple-negative tumors and correlated with the presence of bone and lung metastases, circulating tumor cell count, and clusters. Most of the primary tumors expressing COMP (70%) retained the expression also in the lymph node metastases, which correlated with visceral metastases and reduced survival. In conclusion, COMP appears as a valuable biomarker in metastatic breast cancer patients indicating a more severe stage of the disease. Serum COMP levels were associated with specific types of metastases in patients with metastatic breast cancer emphasizing that further studies are warranted to elucidate its potential role as a monitoring marker.

Download Full-text